You Can Help Researchers Understand Some Groups' Increased Risk of Myeloma
Although major advances have occurred in the diagnosis and treatment of myeloma in the last decade, more needs to be done. A patient survey that takes only a few minutes will help researchers determine the underlying reasons for the increased risk of myeloma in certain races and in family members, and help them understand whether the subtypes of myeloma occur more commonly in one group over the other. Your participation will help all myeloma patients. TAKE PATIENT SURVEY
IMF Patient Advocate Lauded in Hometown Patch
IMF Support Group member Cindy Chmielewski was recognized in the Lawrenceville, New Jersey Patch for her participation in the recent American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The story included a photo of Cindy with Vincent Rajkumar, M.D., a myeloma specialist from the Mayo Clinic. Congratulations, Cindy! READ MORE
Buying Through IMF's Link to Amazon.com Helps Support Myeloma Research, Education
Tom Courbat, Co-Founder of the Inland Empire Multiple Myeloma Support Group in Riverside, California, suggests we remind readers that when they purchase items on Amazon.com using the IMF link to the Amazon.com website, amazon.myeloma.org, they help fund myeloma research and education. As one IMF donor puts it: "I buy everything from refrigerator filters to televisions to garage storage on Amazon.com. And I go through the IMF link. So we get a percentage of everything I spend." Music to our ears! BOOKMARK THE IMF LINK TO AMAZON
Lisa Bence is celebrating her late mother Glenda Margaret Bence at an afternoon tea in her memory on March 2nd in Durham, NC. Inspired by her mom, who Lisa says "was always volunteering her time to give back," Lisa's goal is to raise myeloma awareness and help fund IMF research leading to a cure. Please contact Suzanne Battaglia at sbattaglia@myeloma.org for help in organizing an event or campaign of your own!
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
jc test
10 PASSI PER CURA MIGLIORE®
10 Steps to Better Care® 10 Steps to Stress Control – From Fear to Hope
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique
New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage
Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre
Conference aired at 1:00 pm CEST/7:00 am Eastern/4:00 am Pacific
ABOUT BSRI™
ABOUT BSRI™
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - September 2012
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASH 2012: A PREVIEW
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
Health Reform and You: The ABC’s of the ACA for Private Health Insurance
IMF 6th Annual Comedy Celebration benefiting the Peter Boyle Research Fund October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
It is Officially Myeloma Awareness Month Across the Country!
jc test
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
April 26, 2012
Myeloma Minute
February 7, 2013
Myeloma Minute
July 26, 2012
Myeloma Minute
June 28, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
May 17, 2012
Myeloma Minute
November 8, 2012
Myeloma Minute
October 25, 2012
Myeloma Minute June 13, 2013
Myeloma Minute May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The Hope Society
THE IMF AT ASH 2012
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie September 8,2011
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
Клиническое значение электрофореза белковых фракций
back
print
related videos
related articles
